| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 2 securities · passive | ||||||
|
Freenome, Inc.
13G
FRNM · 35661P100
|
5.2% |
7/27/2026
Event 7/20/2026
|
||||
| AH Bio Fund I, L.P. | 3.1% | |||||
| AH Equity Partners Bio I, L.L.C. | 3.1% | |||||
| Andreessen Horowitz LSV Fund II, L.P. | 1.0% | |||||
| AH Equity Partners LSV II, L.L.C. | 1.0% | |||||
| CLF Partners, LP | 0% | |||||
| AH Equity Partners V, L.L.C. | 0% | |||||
| AH Parallel Fund IV, L.P. | 1.1% | |||||
| AH Equity Partners IV (Parallel), L.L.C. | 1.1% | |||||
| Marc L. Andreessen | 5.2% | |||||
| Benjamin A. Horowitz | 5.2% | |||||
|
CAMP4 Therapeutics Corporation
13G/A
CAMP · 13463J101
|
4.5% |
11/14/2025
Event 9/30/2025
|
||||
| AH Bio Fund I, L.P. | 3.4% | |||||
| AH Equity Partners Bio I, L.L.C. | 3.4% | |||||
| AH Bio Fund IV, L.P. | 1.2% | |||||
| AH Equity Partners Bio IV, L.L.C. | 1.2% | |||||
| Marc L. Andreessen | 4.5% | |||||
| Benjamin A. Horowitz | 4.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.